Literature DB >> 20332012

Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[alpha]anthracene-induced breast tumor in rat.

Rajeev Mishra1, Ashutosh Tiwari, Smrati Bhadauria, Jyoti Mishra, P K Murthy, P S R Murthy.   

Abstract

Centchroman is a non-steroidal oral contraceptive and has been found to be a candidate drug for breast cancer exhibiting partial to complete remission of lesions in 40.5% of breast cancer patients. The therapeutic efficacy of centchroman was monitored alone and together with glycine soya on growth of 7,12-dimethylbenz[alpha]anthracene-induced breast tumor in rat. The tumor regression was monitored at different doses of centchroman alone ranging from 0 to 10 mg kg(-1) and with glycine soya from 1x10(4) to 5x10(4) mg kg(-1) per day until 5weeks treatment. An optimum tumor treatment opus was established with varying treatment parameters including doses of therapeutic agents and treatment period. The tumors were found to be static with a strong anti-estrogenic effect. Overall our study shows that both centchroman and glycine soya alone and jointly combat with breast cancer. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332012     DOI: 10.1016/j.fct.2010.03.029

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  5 in total

1.  Nanoparticle formulation of ormeloxifene for pancreatic cancer.

Authors:  Sheema Khan; Neeraj Chauhan; Murali M Yallapu; Mara C Ebeling; Swathi Balakrishna; Robert T Ellis; Paul A Thompson; Pavan Balabathula; Stephen W Behrman; Nadeem Zafar; Man M Singh; Fathi T Halaweish; Meena Jaggi; Subhash C Chauhan
Journal:  Biomaterials       Date:  2015-03-26       Impact factor: 12.479

Review 2.  Anti-cancer potential of a novel SERM ormeloxifene.

Authors:  Rishi Kumar Gara; Vasudha Sundram; Subhash C Chauhan; Meena Jaggi
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Ormeloxifene efficiently inhibits ovarian cancer growth.

Authors:  Diane M Maher; Sheema Khan; Jordan L Nordquist; Mara C Ebeling; Nichole A Bauer; Lucas Kopel; Man Mohan Singh; Fathi Halaweish; Maria C Bell; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Lett       Date:  2014-10-13       Impact factor: 8.679

4.  A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth.

Authors:  Neeraj Chauhan; Diane M Maher; Murali M Yallapu; Bilal B Hafeez; Man M Singh; Subhash C Chauhan; Meena Jaggi
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

5.  Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses.

Authors:  Lakshmi S; Shanitha A; Shiny Dv; Rahul Bs; Saikant R; Shehna Sharaf; Abi Sa; Rajmohan G
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.